Bank of America just raised its EUR/USD forecast
Gilead Sciences (NASDAQ:GILD) Chief Financial Officer Andrew D. Dickinson sold 2,500 shares of company stock on August 15, 2025, at a price of $118.53. The transaction amounted to $296,325. The sale comes as Gilead, now valued at $146.5 billion, trades near its 52-week high after delivering a remarkable 65% return over the past year.
According to a Form 4 filing with the Securities and Exchange Commission, the sale was executed under a Rule 10b5-1 trading plan adopted on August 29, 2024. Following the transaction, Dickinson directly owns 160,110 shares of Gilead Sciences. InvestingPro analysis indicates the stock is currently undervalued, with additional metrics and 13 exclusive ProTips available through the comprehensive Pro Research Report, offering deeper insights into this prominent biotechnology player’s financial health and growth prospects.
In other recent news, Gilead Sciences reported a solid second-quarter performance, with total sales reaching $7.1 billion and earnings per share of $1.97. This performance led to several analyst firms adjusting their price targets for the company. Mizuho (NYSE:MFG) raised its price target to $131, driven by higher sales estimates for Gilead’s treatment for relapsed/refractory multiple myeloma. Cantor Fitzgerald reiterated an Overweight rating with a $129 price target, noting Gilead’s increased full-year revenue guidance by $500 million, excluding its COVID-19 treatment, Veklury. BofA Securities increased its price target to $140, describing the results as "good overall." RBC Capital adjusted its price target to $98, reflecting Gilead’s strong performance in key HIV and PrEP franchises. Lastly, TD Cowen raised its price target to $115, highlighting a 3% earnings per share beat driven by HIV sales. These developments reflect analysts’ positive outlook following Gilead’s recent earnings report.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.